GENE ONLINE|News &
Opinion
Blog

Feature
How Can Taiwan’s Biopharma Seize the Next Global Business Opportunity? – An Interview with Dr. Jerome Shen
2021-10-17
Expanding Deals and Investments Underscore Burgeoning Market of Targeted Protein Degradation
2021-10-07
2021 BioJapan Highlights: How Can Metabolomics and Lipidomics Deepen Microbiome Research?
2021-10-14
2021 CSCO Highlights: JW Therapeutics, Innovent, Ambrx, HUTCHMED Release Latest Data on Cancer Drugs
2021 Chinese Society of Clinical Oncology (CSCO) officially wrapped on September 29th (Taiwan Time). The event invited global biotechs and pharmaceutical companies to announce their latest oncology research and discovery, especially on tumor diagnosis and treatment.

In the 4-day forum, China’s JW Therapeutics and Innovent Biologics, WuXi AppTec-invested firm Ambrx Biopharma, and Hong Kong’s HUTCHMED present the latest clinical data of their cancer drug.
2021-10-07
Are Digital Therapeutics the Next Generation of Medical Products?
2021-10-12
Special
Apnimed’s Oral Drug for Obstructive Sleep Apnea Registers Encouraging Outcomes in Two Phase 2 Trials
Sleep apnea is a serious disorder characterized by repeated breathing interruptions during sleep. Among the many types of sleep apnea, obstructive Sleep Apnea (OSA) is the most common, affecting 17% of women and 34% of men in the US. The disorder is often underdiagnosed and is estimated to affect more than 25 million Americans.

OSA occurs when throat muscles intermittently relax after sleep and cause partial or complete upper airway closure. As a result, blood oxygen levels get lowered, and the brain briefly wakes patients from their slumber. This often leads to poor sleep and aggravates other medical conditions such as hypertension, diabetes, cardiovascular disease, and stroke. Besides, impaired sleep also affects work productivity, reduces functional ability, and lowers the quality of life.

Cambridge, MA-based Apnimed is a clinical-stage company that aims to develop novel therapies for sleep apnea and related disorders. On October 13th, the company announced top-line results from two Phase 2 trials, APC-003 and APC-004, evaluating AD109, its investigational, oral medicine for patients with OSA.
2021-10-14
Anti-cancer Agent Derived From Himalayan Caterpillar Fungus Shines in Early Trials
Cancer continues to be one of the deadliest diseases on the planet. According to the International Agency for Research on Cancer, in 2018, there were 18.1 million new diagnoses around the world, and about 9.5 million reported deaths.

Last week, NuCana, a UK-based clinical-stage biopharma, announced promising results in an early clinical trial for its potent anti-cancer molecule NUC-7738 derived from Himalayan Caterpillar Fungus.

NUC-7738 is synthesized by researchers at the University of Oxford in partnership with NuCana. Researchers reported encouraging signals of anti-tumor activity and prolonged disease stabilization in patients participating in the ongoing Phase 1 trial, which began in 2019.

NuCana harnesses the power of ProTide technology (phosphoramidate chemistry) to develop next-generation chemotherapeutics designed to overcome the key cancer resistance mechanisms of existing nucleoside analogs. Hugh S. Griffith, Founder and CEO of believes “NuCana is striving to significantly improve outcomes for patients by transforming chemotherapy and pioneering a new era in oncology.”

2021-10-14
Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues
Takeda seems to have embarked on a deal-making binge in the past few days. Just last week, the Japanese pharma giant signed a billion-dollar strategic partnership with Selecta Biosciences to develop targeted gene therapies for lysosomal storage disorders. Yesterday, it emulated that with another massive deal!

On October 11th, Takeda announced a $3.6 billion gene therapy pact with San Diego-based Poseida Therapeutics. The exclusive license agreement aims to utilize Poseida's proprietary technologies for the research and development of up to eight gene therapies.

Speaking to GeneOnline, Eric Ostertag, CEO of Poseida Therapeutics, said both companies are philosophically very aligned in terms of patient care and in trying to get innovative treatments to patients with unmet medical needs, primarily pediatric patients.
2021-10-13
LATEST
How Can Taiwan’s Biopharma Seize the Next Global Business Opportunity? – An Interview with Dr. Jerome Shen
2021-10-17
Axial Therapeutics to Advance Pipeline for Neurological Diseases with $37.25 Million Series C Funding
2021-10-17
Resilience, Harvard University Ink 5-Year Strategic R&D Alliance Leveraging Biomedical Innovation for a Resilient Tomorrow
2021-10-16
Samsung Biologics Initiates Production of Moderna’s COVID-19 Vaccine
2021-10-15
Takeda Collaborates with Immusoft to Advance Treatments in Rare Metabolic Diseases
2021-10-15
Dr. Reddy Stands as the First Indian Firm to Launch Cancer Drug in Chinese Market
2021-10-15
Apnimed’s Oral Drug for Obstructive Sleep Apnea Registers Encouraging Outcomes in Two Phase 2 Trials
2021-10-14
Deals
Axial Therapeutics to Advance Pipeline for Neurological Diseases with $37.25 Million Series C Funding
2021-10-17
858 Therapeutics Launches with $60 Million Series A for Advancing Small-Molecule Drugs
2021-09-23
Allay Therapeutics Raises $60 Million to Finance its Non-Opioid Pain Management Platform
2021-09-16
Oxford Nanopore Soars on London Market Debut
2021-10-05
Cue Health’s $200 Million Nasdaq IPO: Where Will the Ball Roll Next?
2021-09-27
Oxford Nanopore Gears Up for Highly-Anticipated LSE IPO
2021-09-03
M&A
Supernus Invests $400 Million to Acquire New Parkinson’s Assets from Adamas
2021-10-12
Pacira Acquires Flexion for $425 Million to Expand Non-Opioid Painkiller Portfolio
2021-10-12
Amicus Therapeutics Spins Off Its Gene Therapy Unit in a SPAC Deal
2021-10-02
Ranking & Reports
Evolution of Taiwan’s Biotechnology Industry: Policies, Hotspots, and Market Movements
2021-10-05
The 6 Companies Leading the Resurgence in RNA Editing R&D
2021-08-24
10 Precision Oncology Companies to Look Out for
2021-05-27
Categories
How Can Taiwan’s Biopharma Seize the Next Global Business Opportunity? – An Interview with Dr. Jerome Shen
2021-10-17
Revealing the Underestimated Potential of Natural RNA Editing – An Interview with Dr. Trees-Juen Chuang
2021-09-17
Current Challenges and Future Opportunities of Artificial RNA Editing – An Interview with Professor Toshifumi Tsukahara
2021-08-26
Samsung Biologics Initiates Production of Moderna’s COVID-19 Vaccine
2021-10-15
Dr. Reddy Stands as the First Indian Firm to Launch Cancer Drug in Chinese Market
2021-10-15
2021 BioJapan Highlights: How Can Metabolomics and Lipidomics Deepen Microbiome Research?
2021-10-14
Eli Lilly’s Early Breast Cancer Drug Gets FDA Nod but Faces Tricky Rollout
2021-10-14
Takeda Hits the Brakes on Narcolepsy Drug Trials
2021-10-07
Kyowa Kirin, Amgen’s Atopic Dermatitis Drug Delivers Strong Results in Phase 2 Trial
2021-10-05
Hansoh Bets on RNA Interference Technology with $450M+ OliX Deal
2021-10-13
China’s Metabolic Drugmaker Scores $70M Series C to Accelerate Drug Trials
2021-10-13
2021 CSCO Highlights: JW Therapeutics, Innovent, Ambrx, HUTCHMED Release Latest Data on Cancer Drugs
2021-10-07
What are Investors Looking for in a Biotech Startup?
2021-07-27
Primed to Surpass CRISPR: Prime Medicine Emerges Out of Stealth with $315 Million in Funding
2021-07-15
Blackstone Pumps $250 Million in CAR-T Startup, Betting on Intellia’s and Cellex’s Technologies
2021-06-23
Canada Signs Deal with Moderna to Build Vaccine Plant in the Country
2021-08-12
Japan’s Kyowa Inks Deal with Taiwan’s CDMO Firm to Manufacture Generic Drugs
2021-08-06
China’s BeiGene to Build a Biologics Manufacturing Site in the US
2021-08-04
Resilience, Harvard University Ink 5-Year Strategic R&D Alliance Leveraging Biomedical Innovation for a Resilient Tomorrow
2021-10-16
Takeda Collaborates with Immusoft to Advance Treatments in Rare Metabolic Diseases
2021-10-15
Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues
2021-10-13
Could This Anti-Sperm Immunocontraception Work As a Novel Female Birth Control?
2021-08-24
New Study Explores How Sleep Deprivation Inhibits Memory Consolidation
2021-08-07
Kite to Invest in Next Generation Immunotherapy with Appia Bio Collaboration
2021-08-06
CYTENA Bioprocess Solutions Closes $5M Funding to Develop Automatic High-throughput Screening Platform for Pharmaceuticals
2021-10-05Partner
Taiwan’s AMS BioteQ Develops a New Antimicrobial Dressing Which Accelerates Diabetes Wound Healing
2021-09-22 Partner
Foundation Medicine Enters Partnership With Epic to Integrate Genomic Insights into EMR Systems
2021-08-30
EVENT
2021-10-11
Pharma 2021
Virtual
2021-10-25
AusBiotech 2021
Online and on-demand
2021-11-16
RESI Partnering Week
Online
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!